Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07021898 · ClinicalTrials.gov registry record · Phase 1
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
A Phase 1 study of Metastatic Solid Tumors, sponsored by Erasca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 5
- Study locations
NCT07021898: Recruiting Phase 1 study of Metastatic Solid Tumors, sponsored by Erasca.
NCT07021898 is a Phase 1 study of Metastatic Solid Tumors that is actively recruiting participants, run by Erasca. The registered enrollment target is 200 participants, roughly in line with the 196-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target. The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07021898, a Phase 1 study of Metastatic Solid Tumors, is actively recruiting participants, sponsored by Erasca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.
Primary Outcome
Based on toxicities observed
Conditions Studied
Interventions
- DRUG ERAS-4001
- DRUG ERAS-4001 in combination
Study Locations (5)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology - Irving
- NEXT Oncology - San Antonio
Tennessee
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Nashville
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT07021898 shows while recruiting
NCT07021898 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 196-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target.
The record links to 1 condition, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which ERAS-4001 is the first listed.
NCT07021898 lists 5 locations in 3 states (Texas, Tennessee, Washington).
Frequently Asked Questions
What is clinical trial NCT07021898 about?
NCT07021898 is a clinical study titled "A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.". The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.
What is the current status of trial NCT07021898?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2025-08-06. Estimated completion is 2028-12.
What conditions does trial NCT07021898 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors.
What interventions are being tested in trial NCT07021898?
The interventions under investigation include: ERAS-4001 (DRUG), ERAS-4001 in combination (DRUG).
Who is sponsoring clinical trial NCT07021898?
This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07021898 being conducted?
This trial has 5 study locations across Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07021898's enrollment target sits among peer trials
200 8th of 20 higher than 11 of 20 other Metastatic Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SLV-324 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI